276 related articles for article (PubMed ID: 23880851)
1. Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.
Yin L; Hu Q; Hartmann RW
Int J Mol Sci; 2013 Jul; 14(7):13958-78. PubMed ID: 23880851
[TBL] [Abstract][Full Text] [Related]
2. Metastatic castration-resistant prostate cancer: time for innovation.
Tucci M; Scagliotti GV; Vignani F
Future Oncol; 2015; 11(1):91-106. PubMed ID: 25572785
[TBL] [Abstract][Full Text] [Related]
3. [Novel drugs provide better therapy for prostate cancer].
Kellokumpu-Lehtinen P; Tammela T
Duodecim; 2013; 129(9):923-30. PubMed ID: 23786104
[TBL] [Abstract][Full Text] [Related]
4. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
5. Contemporary management of metastatic castration-resistant prostate cancer.
Sonpavde G; Sternberg CN
Curr Opin Urol; 2011 May; 21(3):241-7. PubMed ID: 21455038
[TBL] [Abstract][Full Text] [Related]
6. New agents in the arsenal to fight castrate-resistant prostate cancer.
Ezzell EE; Chang KS; George BJ
Curr Oncol Rep; 2013 Jun; 15(3):239-48. PubMed ID: 23440553
[TBL] [Abstract][Full Text] [Related]
7. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].
Ouzaid I; Ravery V; Pouessel D; Culine S
Prog Urol; 2013 Jan; 23(1):1-7. PubMed ID: 23287477
[TBL] [Abstract][Full Text] [Related]
8. [How to manage patients with CRPC?].
Beuzeboc P; Massard C
Bull Cancer; 2015 Jun; 102(6):509-15. PubMed ID: 26028494
[TBL] [Abstract][Full Text] [Related]
9. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes.
Galsky MD; Small AC; Tsao CK; Oh WK
CA Cancer J Clin; 2012; 62(5):299-308. PubMed ID: 22535487
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
Payne H; Bahl A; Mason M; Troup J; De Bono J
BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
[TBL] [Abstract][Full Text] [Related]
11. Novel and bone-targeted agents for CRPC.
Fizazi K; Albiges L; Massard C; Escudier B; Loriot Y
Ann Oncol; 2012 Sep; 23 Suppl 10():x264-7. PubMed ID: 22987974
[TBL] [Abstract][Full Text] [Related]
12. [Treatment strategies for advanced prostate cancer].
Küronya Z; Bíró K; Géczi L; Németh H
Magy Onkol; 2015 Sep; 59(3):229-40. PubMed ID: 26339912
[TBL] [Abstract][Full Text] [Related]
13. A renaissance in the medical treatment of advanced prostate cancer.
Rove KO; Flaig TW
Oncology (Williston Park); 2010 Dec; 24(14):1308-13, 1318. PubMed ID: 21294475
[TBL] [Abstract][Full Text] [Related]
14. Current clinical trials in castrate-resistant prostate cancer.
Petrylak DP
Curr Urol Rep; 2011 Jun; 12(3):173-9. PubMed ID: 21533748
[TBL] [Abstract][Full Text] [Related]
15. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
[TBL] [Abstract][Full Text] [Related]
16. Novel molecular targets for the therapy of castration-resistant prostate cancer.
Agarwal N; Sonpavde G; Sternberg CN
Eur Urol; 2012 May; 61(5):950-60. PubMed ID: 22209376
[TBL] [Abstract][Full Text] [Related]
17. US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
D'Amico AV
J Clin Oncol; 2014 Feb; 32(4):362-4. PubMed ID: 24344221
[No Abstract] [Full Text] [Related]
18. New treatment options for patients with metastatic castration-resistant prostate cancer.
Higano CS
Cancer Treat Rev; 2012 Aug; 38(5):340-5. PubMed ID: 21944872
[TBL] [Abstract][Full Text] [Related]
19. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
20. Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.
Bambury RM; Rathkopf DE
Urol Oncol; 2016 Aug; 34(8):348-55. PubMed ID: 26162486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
